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IL-1 is recognized as an effector cytokine contributing to
islet -cell destruction during diabetes. We have previously
shown in vitro that IL-1 induces nitric oxide (NO) and -cell
damage. Here, we show that IL-1 administration in vivo to
Wistar rats transiently increases manganese superoxide dis-
mutase activity, whereas inducible NO synthase is not de-
tected, and the levels of nitratenitrate do not change. More-
over, a significant decrease of mitochondrial aconitase,
leading to a rise of hydroperoxides, and islet -cell apoptosis,
involving caspase-3 and -8, is observed. Analysis of adhesion
molecules in -cells showed that intercellular adhesion mol-
ecule-1 is highly expressed 48 h after IL-1 administration and
that this is concomitant to the fall of manganese superoxide
dismutase activity. Thus, IL-1 exerts a proapoptotic effect in
vivo through mitochondrial enzyme alteration, which is not
related to the inducible NO synthase pathway, and dysregu-
lates the immune system through the up-regulation of adhe-
sion molecules. (Endocrinology 144: 4264–4271, 2003)
IL-1-INDUCED CYTOTOXICITY in pancreatic -cells invitro (1), potentiated by other inflammatory mediators
such as TNF- and interferon- (IFN-) (2, 3), has been as-
cribed to increased nitric oxide (NO) release (4). In fact, the
gene encoding for the inducible NO synthase (iNOS) is in-
duced by IL-1 or IL-1 plus IFN- treatment in rodent and
human islets, respectively (4). Human -cells die by apopto-
sis, whereas cytokines lead to both necrosis and apoptosis in
rat and mouse -cells (2). It has been suggested that the
necrotic component in rodent islets is attributable to NO-
induced mitochondrial impairment and consequent de-
creased ATP production. Instead, human islets have better
antioxidant defenses that preserve glucose oxidation and
ATP production, allowing cells to complete the apoptotic
program after the death signal triggered by cytokines (3).
Reactive oxygen species (ROS), free radicals, and other
mitochondrial intermediates control the cytotoxic and gene-
regulatory effects of cytokines on -cells, thus providing
bidirectional communication between mitochondria and nu-
cleus. In fact, it has been widely demonstrated that inflam-
matory cytokines trigger complex signaling cascades, often
resulting in excessive ROS production at the mitochondrial
level with damage to cellular components. Manganese su-
peroxide dismutase (MnSOD), a vital antioxidant enzyme
localized into the mitochondrial matrix, acts as a cellular
defense to detoxify these ROS. Islet -cells contain extremely
low levels of superoxide dismutase (SOD) (5, 6); and, with
multiple low-dose streptozocin-induced diabetes, these lev-
els are even further decreased (7). Administration of free
radical scavengers partially protect islet -cells from both
alloxan- and streptozotocin-induced damage (8, 9).
Several cytokines, such as TNF-, elicit elevations of both
mRNA and protein levels of MnSOD (10). Administration of
recombinant IL-1 induces MnSOD expression in rat pan-
creatic islets (11, 12). An increase in the level of this antiox-
idant enzyme has been shown to be cytoprotective, even if
the pathways determining MnSOD expression are still
unclear.
The effect of IL-1, when administered in vivo, is more
complex, and contradictory effects have been reported (for a
review, see Ref. 13). Systemically administering low doses of
IL-1 to Bio Breeding rats resulted in a significant reduction
of diabetes incidence, whereas high doses of the same cyto-
kine accelerated the disease (14). Conversely, systemic ad-
ministration of a wide variety of cytokines has been dem-
onstrated to both prevent and suppress diabetes, irrespective
of their effect in vitro. This is not surprising, because systemic
administration of a given cytokine may affect the production
and action of other cytokines, resulting in changes different
from those induced by the endogenous cytokine (13).
Furthermore, circulating forms of intercellular adhesion
molecule (cICAM)-1 have been detected in human serum
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(15), and its enhancement has been described in several in-
flammatory and immune diseases (16–18). Recently, it has
been postulated that cICAM-1 expression on cell membranes
and in serum is regulated by different and independent
mechanisms via proteolytic cleavage (19). In fact, it has been
demonstrated that adhesion molecules, such as ICAM-1, are
up-regulated by cytokines (20) or by SODs in vitro (21).
To further address the IL-1 in vivo effects in rat islet
-cells, we administered exogenous IL-1 in the nearest ar-
terial supply to the pancreas and examined the outcome on
purified islet cells. We found that IL-1 induces stimulation
of MnSOD activity and concomitant disruption of mitochon-
dria with activation of caspase-3 and -9.
Materials and Methods
In vivo treatment
Wistar rats, 10–12 wk old, were housed in our facility, under standard
laboratory conditions, with free access to food and water. For in vivo
administration, rats were anesthetized and a midline incision made. The
major trunk of the pancreatic-duodenal artery was evidenced; and each
animal received, through this artery, an infusion of 5.0 ml human IL-1
(280 U/ng), at a concentration of 4.0 g/kg body weight (Sigma, Milan,
Italy) (22). Similar volumes (5 ml) of vehicle were administered to the
control animals. The animals were killed 12 h, 24 h, and 48 h later. In a
first series of experiments, observations were made up to d 5; but,
because of the fact that a large number of animals were affected by a
pancreatitis, because of the combination of the use of cytokine and the
abdominal surgical intervention, we decided to stop our observation at
48 h (d 2).
Islet preparation
At the end of treatment, each pancreas was removed and suspended
in buffered Hanks’ solution at 4 C, dissected free from extraneous fat,
and minced with scissors. Tissue was incubated at 37 C with vigorous
shaking for 15–20 min in 5 ml Hanks’ solution containing 1.6 mg/ml type
V collagenase (Sigma). After centrifugation (500 g, 15 min), the pellet was
washed twice. Islets were then isolated on a Ficoll gradient. We obtained
isolated islets with a purity more than 90% yields of at least 1,500
islets/ml medium. In addition, untreated animals were used for islet
isolation and culture with IL-1 (3 ng/ml). Briefly, the islets were pre-
cultured at 37 C in a 5% CO2 humidified air atmosphere for 3–6 d in
RPMI 1640 medium (Sigma), supplemented with 10% fetal calf serum.
Free-floating islets, 300 per 3 ml medium, were then cultured for another
2 d with 3 ng/ml human recombinant IL-1 (Sigma). At the end of the
in vitro experiments, islets were collected, and RNA was extracted for
RT-PCR analysis. The rationale of these experiments, made in triplicate,
was to obtain a positive control for both MnSOD and iNOS mRNA
transcripts and for comparison with the in vivo results.
Insulin levels
Insulin levels from peripheral blood were examined using RIA kits
(Bio-Rad, Milan, Italy). Values are expressed as mm.
Fasting blood glucose levels
Blood glucose levels were determined using One-Touch profile
(Lifescan Inc., Milpitas, CA) daily. Rats were considered hyperglycemics
when their blood glucose levels were higher than 12 mm but lower than
15 mm and diabetics when their blood glucose levels exceeded 15 mm
in two successive determinations.
MnSOD activity
In triplicate experiments, isolated islets were homogenized (Ultra
Turrax mechanical blender) in 100 vol of 10 mm phosphate buffer (pH
7.4), supplemented with 30 mm KCl. Briefly, the homogenates were
sonicated for 1 min at 4 C with a Branson B12 sonicator and left for 30
min to allow solubilization of the enzyme. After centrifugation at
20,000  g for 30 min at 4 C, the supernatants were removed and stored
at 70 C. MnSOD activity was measured using the RanSOD kit (Randox,
Crumlin, Antrim, UK). This method uses xanthine and xanthine oxidase
to generate superoxide radicals, which react with 2-(4-iodophenyl)-3-
(4-nitrophenol)-5-phenyltetrazolium chloride to form a red formazan
dye. The SOD activity was measured by percentage inhibition of xan-
thine to water and molecular oxygen. The results are given as units per
milligram of protein, a unit being the degree of inhibition of the reaction.
The intra- and interassay coefficients of variation were, respectively, less
than 2 and 4.5%. Because of the absence of hemoglobin, there was no
need to correct the enzyme activities. The detection limit was 2 U/mg.
Nitritenitrate levels
In triplicate experiments, at least 150 islets, belonging to in vivo IL-
1-treated animals, were incubated for 30 min at 37 C in 5% CO2 in 300
l Krebs-Ringer-Bicarbonate (KRB) buffer [25 mm HEPES (pH 7.4), 115
mm NaCl, 24 mm NaHCO3, 5 mm KCl, 2.5 mm CaCl2, 1 mm MgCl2, 3 mm
d-glucose, 0.1% BSA]. Nitrite/nitrate was measured after conversion of
nitrate to nitrite with Aspergillus nitrate reductase (Sigma). After mixing
0.1 ml supernatant with 0.1 ml Griess reagent (equal parts of 1.3%
sulfanilamide in 60% acetic acid and 0.1% naphthyl-ethylene-diamine
HCl in water) and incubating for 10 min at room temperature, nitrite was
measured at 540 nm in a Gilford spectrophotometer and compared with
a standard curve with known nitrite levels. The intra- and interassay
coefficients of variations were less than 15%, and the detection limit
was 1 m.
Total plasma antioxidant capacity (TRAP)
The assay, originally described by Rice-Evans and Miller (1994) (23)
is based on the quenching of the ABTS (2,2-azinobis-(3-ethylebenzo-
thiazoline-6-sulfonic acid) radical cation (ABTS  ) by antioxidants. In
the method, ABTS   is produced by the interaction of ABTS with fer-
rylmyoglobin radical species, generated by the activation of metmyo-
globin with H2O2. In our assay procedure, ABTS (150 m), and plasma
(25 l) were mixed together, and the reaction was started by the addition
of H2O2 (75 m). ABTS
  formation was continuously monitored by
absorbance increase at 734 nm, at 20 C. The delay or inhibition-time
between the addition of H2O2 (time zero) and the onset of absorbance
increase (ABTS   formation) was measured. All the reagents were dis-
solved in phosphate buffer treated with Cheelex-100 and containing
DTPA (0.1 mm) to prevent any metal-catalyzed oxidation. The assay was
standardized using Trolox, a water-soluble vitamin E analog. Experi-
ments were performed in triplicate, and the intra- and interassay coef-
ficients of variation for this method were 6.5 and 8.6%, respectively.
Lipid peroxidation products
Plasma lipids were extracted using a modification of the method of
Folch et al. (1957) (24). A mixture of 3.8 ml of 2:1 (vol/vol) chloroform-
methanol was added to 0.2 ml plasma. The mixture was vigorously
mixed (using a vortex) for 2 min, and then 1.0 ml distilled water, acidified
to pH 2.5 with 0.1 n HCl, was added. After agitation with a vortex for
2 min, the suspension was centrifuged at 3000 rpm for 5 min at 4 C. The
lower chloroform lipid layer was removed, vacuum-dried in a Savant RC
100 Speed-Vac concentrator (Savant Instruments, Farmingdale, NY),
and resuspended in 100 l HPLC-grade methanol for hydroperoxide
measurement. The hydroperoxide content of plasma was determined
with the ferrous oxidation (FOX) Version II assay for lipid ROOHs (lipid
hydroperoxide in xylene orange) (FOX2) (25). This technique relies on
the rapid hydroperoxide-mediated oxidation of Fe (2) under acidic con-
ditions. Fe (3) forms a chromofore with xylenol orange, which absorbs
strongly at 560 nm. FOX2 reagent was prepared by dissolving xylenol
orange and ammonium ferrous sulfate in 250 mm H2SO4 to final con-
centrations of 1 and 2.5 mm, respectively. One volume of this concen-
trated reagent was added to 9 vol HPLC-grade methanol containing 4.4
mm BHT to make the working reagent, which comprised 250 m am-
monium in 90% (vol/vol) methanol. The working reagent was routinely
calibrated against a solution of H2O2 of known concentration. Aliquots
(90 l) of plasma lipid extracts in HPLC-grade methanol were trans-
ferred into 1.5-ml microcentrifuge vials. Triphenylphosphine in meth-
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anol (10 l of 10 mm) was added to the blank samples to selectively
reduce ROOHs to hydroxyl derivatives having no reactivity with Fe (2).
Methanol (10 l) was added to the test sample. All vials were then
vortex-mixed and incubated at room temperature for 30 min before the
addition and mixing of 900 l FOX2 reagent. After incubation at room
temperature for a further 30 min, the vials were centrifuged at 12,000 
g for 10 min. The absorbance of the supernatant was then read at 560 nm.
Hydroperoxide content in the plasma samples was determined as a
function of the mean absorbance difference of samples with and without
elimination of ROOHs by triphenylphosphine. Experiments were per-
formed in triplicate, and the intra- and interassay coefficients of variation
for this method were 5.0 and 6.8%, respectively.
Mitochondrial aconitase levels
Islets (at least 3000/condition) were dispersed into individual cells
with dispase (0.25 mg/ml) in Ca2- and Mg2-free Hanks’ solution (15
min at 31 C), filtered (60-m nylon screen), and placed in medium
CMRL-1066 (Life Technologies, Inc., Milan, Italy) supplemented with 2
mm l-glutamine, 10% heat-inactivated fetal bovine serum, 50 U/ml
penicillin, and 50 mg/ml streptomycin. They were then incubated (18
h at 37 C); isolated by centrifugation (800 g, 4 C); resuspended in buffer
(5 ml of 250 mm sucrose, 20 mm HEPES, 10 mm MgCl2, 2 mm KH2PO4,
1 mm EGTA, pH 7.4); permeabilized with digitonin (0.007%, 30 min on
ice); agar-isolated by centrifugation; lysed by treatment with Triton
X-100, 30 mm NaCl, 30 mm Tris-Cl, pH 7.4; and centrifuged (5000  g,
4 C, 15 min). Supernatant aconitase activity was measured spectropho-
tometrically (340 nm, 21 C in 20 mm citrate, 0.5 mm NADP, 0.5 mm Mn
Cl2, 50 mm Tris-Cl, pH 7.4, 1 U isocitrate dehydrogenase; total volume
1 ml). Experiments were done in triplicate. Intra- and interassay coef-
ficients of variation for this method were, respectively, less than 3% and
less than 6.5%. Values are expressed as (pmol/100 islets)  (hour  sd).
SOD and iNOS mRNA levels
Total RNA was extracted from 200–250 rat islets by homogenization
in 4 m guanidinium thiocyanate containing 17 mm sodium N-lauryl-
sarcosinate, 25 mm citrate buffer, 0.1 m 2-mercaptoethanol, and a 30%
aqueous emulsion of 0.1% of Antifoam A (Sigma). RNA was precipitated
with ethanol, pelleted, and reextracted with 8 m guanidine hydrochlo-
ride:0.5 m EDTA (19:1). After pelleting and drying, samples were ex-
tracted twice with phenol:chloroform (1:1) and precipitated with etha-
nol. cDNA synthesis was carried out from total RNA with Superscript
reverse transcriptase kit (Life Technologies, Inc.), using oligo (dt)12–18
and Moloney murine leukemia virus reverse transcriptase (20 U) in a
25-l reaction at 37 C for 1.5 h. The solution containing cDNA was
diluted 30, 90, and 270 times in sterile water. Semiquantitative PCR
amplification was carried out on the cDNA from each animal using 3 l
of each dilution of cDNA in a 20-l reaction with 80 ng of each primer,
0.25 mm of each deoxynucleotide triphosphate, 2.5 Ci of (-32P) de-
oxycytidine triphosphate (3,000 Ci/mmol; DuPont NEN Life Science
Products, Milan, Italy), 1 U AmpliTaq (Perkin-Elmer/Cetus, Monza,
Italy), and 3 mm MgCl2. The oligonucleotide primer sequences were:
for MnSOD, 5-ATTAACGCGCAGATCATGCAG-3(forward) and 5-
TTTCAGATAGTCAGGTCTGACGTT-3 (reverse); and for iNOS,
5-AGCTTCTGGCACTGAGTAAAGATA-3 (forward) and 5-
TTCTCTGCTCTCAGCTCCAAG-3 (reverse). Glyceraldehyde-3-
phosphate dehydrogenase housekeeping gene in rat islets was used as
a positive control; the primers were: 5-ACCACAGTCCATGCCAT-
CAC-3 (forward) and 5-TCCACCACCCTGTTGCTGTA-3 (reverse).
The RT-PCR analyses were made in triplicate using a PTC-100 thermal
cycler (MJ Research, Watertown, MA). The amplification products were
separated on a 1.5% agarose gel and stained with ethidium bromide
and were compared with DNA reference markers. As specified above,
the in vitro experiments were used to obtain a positive control for both
MnSOD and iNOS mRNA transcripts. The intensities of the bands were
quantified in an Ultrascan XL Enhanced Laser densitometer (LKB,
Bromma, Sweden) and expressed in arbitrary units of OD.
Determination of caspase activation
Islets were treated with ribonucleases for different time-intervals. At
the end of treatment, colorimetric protease assays kits for caspase-3, -8,
and -9 were used (Alexis Biochemicals, San Diego, CA). These assays,
made on islet extracts, are based on the spectrophotometric detection of
the chromophore p-nitroanilide after cleavage from the labeled sub-
strate. The p-chromophore p-nitroanilide light emission is quantitated
by spectrophotometric determinations at 400 or 405 nm. Briefly, the
caspase-3/CPP32 kit assays the activity of caspase-3 that recognizes
the amino acid sequence DEVD-pNA; the Flice/caspase-8 kit assays the
activity of caspase-8 that recognizes the sequence IETD; the caspase-9/
Mch6 kit assays the activity of caspase-9 that recognizes the sequence
LEHD. Comparison of the absorbance of pNA from a treated sample
with an untreated control allowed the determination of the increase in
caspase activity. For each time point, results from three independent
experiments were averaged.
Apoptosis evaluation
The TUNEL technique was used to detect DNA strand breaks in situ.
Islets, double-stained with fluorescein isothiocyanate and PI, were fixed
on glass slides with 50% glycerol in PBS. Fluorescence was monitored
with a Leica TCS NT laser scanning confocal microscope (Leica, Laser-
technik, Heidelberg, Germany), with excitation from the 488-nm line of
an argon/krypton laser. Fluorescence emission was detected with a
band-pass filter (Chroma Technology, Brattleboro, VT) centered at 530
nm for fluorescein isothiocyanate and above 590 nm for PI. Several
confocal images were used for continuing the number of apoptotic cells.
In each condition, a minimum of 1000 cells from three to eight different
isolations was counted.
cICAM-1 levels
Soluble ICAM-1 activity was assayed using the ELISA CD54 kit
(Endogen, Woburn, MA). Blood samples from each animal were col-
lected from the retroorbital plexus and processed following the kit’s
instructions. Values were expressed as nanograms per milligram.
ICAM-1 expression on islet cells
Samples from the tail of each pancreas were collected and kept frozen
in liquid nitrogen. Randomly selected cryocut sections were stained by
the avidin-biotin peroxidase indirect staining method. The monoclonal
antibody anti-ICAM-1 was a mouse antirat (Santa Cruz Biotechnology,
Santa Cruz, CA). The secondary antibody was biotinylated goat anti-
mouse antibody. As a negative control, the primary Ab was replaced
with goat nonimmune serum. Sections of 5-m thickness were examined
for semiquantitative analysis. The immunoreactive cells on alternate
sections were determined at a magnification of 400 using an eyepiece
with a square-ruled grid with a total area of 0.062 mm2 and were counted
with the M4 image analysis system (Imaging-Brock University, St.
FIG. 1. Effect of in vivo-administered IL-1 on islet cell MnSOD ac-
tivity. Kinetics of MnSOD activity performed on purified pancreatic
islets from rats exposed to IL-1. Results are shown as mean values 
SD and are representative of three independent experiments. *, P 
0.01; **, P  0.001.
4266 Endocrinology, October 2003, 144(10):4264–4271 Todaro et al. • In Vivo IL-1 in Rat Islets
Catherine, Ontario, Canada) in 60 different areas. This allowed the
calculation of immunoreactive cells/mm2  sem. Three different re-
searchers carried out the observations blindly.
Statistical analysis
Student’s t test and ANOVA (when appropriate) were used for sta-
tistical analyses. P values  0.05 were considered significant.
Results
Systemic treatment with IL-1 significantly altered islet
MnSOD activity (Fig. 1), In fact, activity in freshly purified
rat islet cells was significantly enhanced after 24 h 82  2.73
U/mg protein; P  0.01) as compared with cells purified
from control animals (42  9.95 U/mg protein). Thereafter,
enzyme levels decreased considerably (16  5.47 U/mg pro-
tein at 48 h; P  0.001 vs. 12 h).
Supporting evidence for this transient activation of
MnSOD, followed by a statistically significant decrease, was
obtained at the transcriptional level. RNA samples extracted
from purified islet-cell homogenates were analyzed by RT-
PCR. We found that MnSOD mRNA levels were 2-fold
higher at 12 h (7.4  0.23 OD; P  0.001), as compared with
levels at time 0 (4.5  0.15 OD). Interestingly, MnSOD mRNA
levels at 24 h were not similar to levels at time 0 (3.32  0.21
OD) and were barely or not detectable at 48 h (Fig. 2A and
Table 1A). Similarly, analysis of rat islet cells exposed in vitro
to 3 ng/ml IL-1 demonstrated an up-regulation of MnSOD
mRNA levels at 24 h (4.62  0.17 OD) and a down-regulation
at 48 h (2.1  0.1 OD vs. 3.48  0.10 OD; P  0.001) (Fig. 2B
and Table 1B). Furthermore, after in vivo IL-1 administra-
tion, iNOS transcripts, assessed on purified islet, were al-
ways undetectable (Fig. 2A), whereas they were clearly ob-
served after in vitro exposure to IL-1 for 24 h (Fig. 2B). Thus,
it was hypothesized that IL-1 mediated its effects by dis-
ruption of mitochondrial-enzyme activity in islet -cells.
Therefore, we next investigated whether IL-1 modulates
mitochondrial aconitase activity essential for Kreb’s cycle
function. After 48 h of in vivo administration, IL-1 induced
a considerable decrease in mitochondrial aconitase activity in
dispersed pancreatic islet cells (4  0.6 pmol/100 isletsh, P 
0.0001), as compared with control cells (22  4 pmol/100
isletsh) (Fig. 3A). These data suggest that disruption of mi-
tochondria of islet cells could be directly dependent on IL-1
secreted by pancreas-infiltrating macrophages associated
with -cell depletion during the acute phase of diabetes.
To rule out the possibility that NO contributes to rat islet cell
injury during diabetes, islet cells from in vivo IL-1-treated
animals were analyzed for the levels of nitritenitrate, as an
indirect sign of nitrogen radicals and iNOS involvement. As can
FIG. 2. IL-1 regulates SOD and iNOS mRNA levels on pancreatic
islet cells. A, RT-PCR analysis of MnSOD and iNOS mRNA tran-
scripts on islet homogenates purified from animals exposed to IL-1;
B, mRNA transcripts of MnSOD and iNOS in control pancreatic islets
treated in vitro with IL-1. Loading controls were performed by de-
tecting glyceraldehyde-3-phosphate dehydrogenase. One representa-
tive of three independent experiments is shown.
TABLE 1A. ODs (arbitrary units) in vivo
Hours 0 12 24 48
Mn SOD 4.5  0.15 7.4  0.23a 3.32  0.21
iNOS
GAPDH 3.2  0.11 3.0  0.08 3.1  0.01 2.9  0.05
Values are averaged and representative of three different exper-
iments.
a P  0.001.
TABLE 1B. ODs (arbitrary units) in vivo
Hours 0 12 24 48
Mn SOD 3.48  0.10 3.96  0.11 4.62  0.17 2.1  0.1a
iNOS 1.82  0.08 2.24  0.08a
GAPDH 3.2  0.05 3.1  0.08 3.1  0.13 2.9  0.14
Values are averaged and representative of three different exper-
iments.
a P  0.001.
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be observed in Fig. 3B, islet cells were not reactive for
nitritenitrate, demonstrating that nitrogen radicals are not
directly involved in rat islet -cell destruction.
To better understand the degree of islet -cell survival and
function, including the ability of these cells to counteract
oxidative radical injuries, levels of some antioxidant param-
eters were measured in the plasma of in vivo IL-1-treated
rats. TRAP remained unmodified up to 12 h, whereas it
significantly decreased at 24 h (606.6  11.5 m) and 48 h
(490  75.5 m; P  0.001), as compared with control animals
at the same time points (943.3  37.8 m and 950  36.1 m,
respectively) (Fig. 3C). Similarly, the antioxidant ability of
hydroperoxides in the plasma, as an index of ongoing lipid
peroxidation, was greatly increased at 24 and 48 h (P  0.001
vs. controls) (Fig. 3D).
Furthermore, in vivo islet -cell function was followed by
monitoring glucose and insulin levels in the peripheral blood
of animals exposed to exogenous IL-1. In vivo IL-1 ad-
ministration substantially increased blood glucose levels af-
ter 24 h (8.08  0.16 mm) and 48 h (10.06  0.3 mm, P  0.001
vs. controls and time 0) and concomitantly reduced insulin
levels (89.8  6.7 mm and 73  9.89 mm, respectively, P 
0.0001 vs. controls and time 0), further demonstrating the
significant impairment of islet -cell function. (Fig. 4).
The ability of IL-1 to induce -cell destruction by the
apoptotic machinery was tested, on purified pancreatic islets,
by a colorimetric protease assay for the analysis of caspase-3,
-8, and -9 activity. In vivo IL-1 treatment induced significant
activity of both caspase-3 and -9, whereas negligible
caspase-8 activity was detected (Fig. 5A). In particular, the
increased activity of caspase-3 and -9 was detected early, at
12 h and 24 h (P  0.001 vs. controls and time 0) and increased
dramatically at 48 h (15.36  0.56 mm for caspase-3 and
14.83  0.68 mm for caspase-9, P  0.0001 vs. controls and
time 0), whereas apoptosis analysis showed an abundant
number of apoptotic events at 48 h (70.1  0.4 cell %; P 
0.0001) (Fig. 5B). These data confirm that IL-1 indirectly
participates in the induction of the mitochondrial apoptotic
mechanism in rat islet -cells.
We further studied the possible effects exerted by the
cytokine on the immune system, by monitoring the activity
of adhesive molecules. According to our data, cICAM-1 lev-
els, assessed on blood samples from the retroorbital plexus,
did not significantly change up to 24 h (Fig. 6A); whereas, at
the same time point, MnSOD activity was high (Fig. 1). In
contrast, at 48 h, ICAM-1 levels were significantly enhanced,
up to values considerably higher than those found in controls
and in IL-1-treated animals at 12 and 24 h (278  23 ng/ml;
P  0.001) (Fig. 6A). To determine ICAM-1 expression more
accurately, cryostat sections of pancreas from IL-1-treated
animals were analyzed by immunohistochemistry. We found
that ICAM-1 was scarcely expressed on islet cells from IL-
1-treated animals at time 0 but potently up-regulated at 24
FIG. 3. Mitochondrial aconitase and total antioxidant capability are
modulated by in vivo IL-1 administration. A, Time course of mito-
chondrial aconitase activity performed on dispersed pancreatic islet
cells from controls and IL-1-treated rats. B, Nitritenitrate levels
detected in samples as in A. C, Evaluation of TRAP, at different time
points, on plasma collected from rats after in vivo IL-1 administra-
tion. D, Analysis of hydroperoxide activities on plasma harvested from
control and IL-1-treated animals. Data are mean  SD of three
independent experiments. *, P  0.001; **, P  0.0001.
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and 48 h (Fig. 6, B and C; Table 2). Thus, IL-1 regulates the
mechanism responsible for initiating and amplifying the au-
toimmune process.
Discussion
Our in vivo observations partially agree with previously
reported in vitro observations (12, 26) of an early, but tran-
sient, increase in MnSOD activity after IL-1 administration.
In fact, in vivo experiments have evidenced a MnSOD in-
duction shorter and less intense than in vitro induction (12,
26). MnSOD transcripts after IL-1 challenge in vivo were
clearly evidenced by RT-PCR after 24 h, but they became
undetectable already at 48 h. On the other hand, mRNA
transcripts of iNOS were undetectable in vivo, whereas they
were clearly observed in in vitro experiments; similarly,
nitritenitrate levels were unmodified in vivo but signifi-
cantly increased in vitro (26).
The suppression of MnSOD activity in vivo at 48 h coin-
cides with the impairment of islet -cell functions. SOD is a
group of enzymes that protects cells against toxic oxygen
radicals. These enzymes convert superoxide to molecular
oxygen, and hydrogen peroxide is subsequently converted to
water and oxygen by catalase and various peroxides. By
removing superoxide, SOD prevents the formation of the
highly toxic hydroxyl radical that probably explains much of
the tissue damage that accompanies superoxide and hydro-
gen peroxide formation. Indeed, generation of free oxygen
radicals has been suggested to mediate IL-1’s action on islet
-cells (8) that normally contain relatively low levels of SOD
(5). In fact, streptozotocin-induced diabetes, as well as the
spontaneous development of type 1 diabetes in animal mod-
els, is associated with lower SOD levels. Administration of
scavengers has been found to counteract this reduction (5, 9).
It has been recently demonstrated that an improvement of
the mitochondrial antioxidant defense status prevents NF-kB
activation and iNOS expression in islet -cells, leading to the
thought that MnSOD overexpression may contribute to
-cell survival (27) through the suppression of oxygen free
radical formation.
Interestingly, in our experiments, a severe impairment of
mitochondrial functions takes place; in fact, mitochondrial
aconitase activity was clearly reduced after in vivo admin-
istration of IL-1, reinforcing the thought that IL-1 impairs
mitochondrial antioxidant enzyme activity. Mitochondrial
aconitase is a 4Fe-4S-cluster-containing enzyme involved in
the Kreb’s cycle and is affected by nicotinamide adenine
dinucleotide (NAD) depletion (28). Moreover, the decrease
of TRAP levels, together with the increase of plasma hy-
FIG. 4. IL-1 in vivo exposure regulates islet -cell function. Eval-
uation of glucose (A) and insulin levels (B) on peripheral blood col-
lected from control and IL-1 administered in vivo to animals for 0,
12, 24, and 48 h. Data are mean  SD of three independent experi-
ments. *, P  0.001; **, P  0.0001.
FIG. 5. In vivo IL-1 administration induces pancreatic islet cell
death. A, Detection of caspase (casp)-3, -8, and -9 activity in freshly
purified islets from control and IL-1-treated rats up to 48 h. B, Cell
death percentage of cells treated as in (A) performed by TUNEL assay.
Data presented are mean  SD of three independent experiments. *,
P  0.001; **, P  0.0001.
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droperoxide, a signal of ongoing lipoperoxidation, is con-
sistent with the evidence that this cytokine, administered in
vivo, acts by impairing all antioxidant functions, including
those within islet -cells. The highest levels of lipoperoxi-
dation were quickly reached, and this was soon followed by
a significant increase of apoptotic islet cells. Alterations of
antioxidant function were detected in plasma in our exper-
iments; moreover, they were mainly not evident until 24 h,
whereas the increase in caspase activity and the decrease in
insulin levels were already observed within 12 h. We and
other researchers have previously reported, in several stud-
ies, that oxygen free radicals may contribute to the islet -cell
destruction in type 1 diabetes animal models and have sug-
gested that free radical scavengers significantly increased
SOD, catalase, and glutathione peroxidase and reduce the
antioxidant status impairment, although they were not able
to fully counteract the progression of the disease (5–9, 29).
Thus, the impairment of antioxidant function may serve to
worsen the alterations that have been initiated by IL-1, but
it does not represent the initiating event.
These above-reported alterations happen without iNOS
and nitritenitrate changes. This leads to the observation
that IL-1-induced death in vivo is not related to the iNOS
pathway.
Interestingly, in vivo administration of IL-1 up-regulates
adhesion molecules. In particular, the levels of cICAM-1
were first decreased after 24 h and were enhanced, together
with islet-cell expression of adhesion molecules. Adhesion
molecule enhancement has been found in inflammatory and
immune disorders (16–18), and up-regulation is clearly as-
sociated with ongoing dysregulation of the immune system.
The latter is of significance because of the involvement of the
cytokine in immunity.
In summary: 1) IL-1-induced MnSOD activation takes
place also when the cytokine is administered in vivo, as in
vitro, although this transient induction, of lower intensity, is
already and completely reversed by 48 h; 2) the cytotoxicity
FIG. 6. Expression of ICAM-1 on pancreatic islet cells exposed to IL-1. A, Kinetics of cICAM-1 levels detected in blood samples from each animal
control and IL-1-treated animals and collected from the retroorbital plexus. B, Immunohistochemical analysis of ICAM-1 on cryostat sections
of pancreatic gland from animals exposed to IL-1 for 0 h (B), 24 h (C), and 48 h (C) and revealed by diaminobenzidine (brown staining; original
magnification, 300). One representative of three independent experiments is shown.
TABLE 2. ODs (arbitrary units) in vivo
Hours 0 12 24 48
ICAM-1 20.4  3.33a 12.5  1.77
Values are averaged and representative of three different exper-
iments.
a P  0.001.
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of IL-1, when administered in vivo, does not involve the
activation of iNOS; 3) plasma lipid peroxidation and then
apoptosis of islet -cells are observed; 4) caspase-3 and -9
activity was increased very early on, thus the mitochondrial
pathway is involved during islet -cell death; and 5) adhe-
sive molecules are up-regulated in islet cells, leading to the
involvement of the immune system.
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